Receiver operating characteristic curve analysis indicated a maximum optimal cut-off cycle threshold value of 10.32 for differentiating pathological responders from non-responders, with a sensitivity of 80.0% and specificity of 88.2%. These data showed that miR-21 was significantly overexpressed in CRC tumour tissue and was associated with advanced CRC, and that miR-21 may be a potential candidate biomarker for predicting pathological tumour response to chemotherapy.
Introduction
Colorectal cancer (CRC) is a major public health problem, accounting for 10 -15% of all cancers worldwide. 1 Although 5-year mortality rates have decreased over the last three decades, 2 CRC is still the second leading cause of cancer-related death in Western countries. Approximately half of newly-diagnosed patients develop micrometastases and die of their disease. 3 Multimodal treatment strategies involving surgery, chemotherapy and radiotherapy have been explored to improve the survival of these patients. Since the first reports in the late 1990s, the FOLFOX regimen 4 (bolus/infusion of fluorouracil with folinic acid modulation and oxaliplatin) has become one of the most common first-line treatments for patients with advanced CRC. Tumour cells often, however, show resistance K Liu, G Li, C Fan et al.
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to anticancer drugs, making chemotherapy ineffective. Previous investigations have identified a variety of molecules associated with the initiation, progression and drug response of CRC. 5, 6 The precise molecular mechanisms remain unclear and biological markers with high sensitivity and specificity for the diagnosis of CRC and prediction of chemotherapeutic response are still lacking.
MicroRNAs (miRNAs) are small noncoding RNAs that are 18 -25 nucleotides in length and have important functions in various biological processes, such as development, cellular differentiation, proliferation and apoptosis. 7 So far, 474 mature miRNAs have been reported in the human genome, with computational prediction estimates > 1000. 8 As posttranscriptional regulators of protein synthesis, miRNAs can bind to target mRNA and either degrade it or suppress its translation. 9 Investigations have revealed aberrant expression of miRNAs in cancer and proven their function as oncogenes or tumour suppressors, depending on their target. 10, 11 Furthermore, miRNAs are associated with sensitivity or resistance to chemotherapeutic drugs, such as cisplatin or 5-fluourouracil, in various cancers. 12 -15 Specifically, miR-21 has been shown to be upregulated in gastric cancer, 16 Tissue samples were obtained before and after treatment. Prior to treatment, pairs of enteroscopy biopsies were collected from each patient from the primary colorectal tumour and from normal adjacent tissue (NAT) > 2 cm from the cancer tumour. Biopsies were flash frozen and stored at −80°C in liquid nitrogen prior to analysis of miR-21 expression. After treatment, the patient's response to chemotherapy was assessed histologically using resected tissue.
TREATMENT AND BIOPSY

ASSESSMENT OF MIR-21 EXPRESSION
Total RNA was isolated from 20 -50 mg of pretreatment CRC and NAT biopsies using TRIzol ® reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. RNA quality and quantity were assessed using a Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, CA, USA). Expression of miR-21 was assessed by quantitative real-time reverse transcriptionpolymerase chain reaction (RT-PCR). For each sample, 5.5 ng of total RNA was reverse transcribed into single-stranded cDNA in a 15 µl reaction volume using the TaqMan ® MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). In the realtime PCR step, the cDNA was amplified using sequence-specific primers from the TaqMan ® MicroRNA Assays Human Panel together with TaqMan ® Universal PCR Mastermix on an Applied Biosystems 7900HT sequence detection system (all from Applied Biosystems). All samples were processed in triplicate.
The cycling programme involved preliminary denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 94°C for 15 s, annealing at 55°C for 30 s, and elongation at 70°C for 30 s, followed by a final elongation step at 70°C for 5 min. The cycle threshold (CT) was recorded and the amount of miR-21 relative to the internal control small nuclear RNA U6 was calculated using the equation 2 −∆CT where ∆CT = (CT miR-21 − CT U6 ).
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EVALUATION OF RESPONSE TO CHEMOTHERAPY
All resection specimens were evaluated according to a standardized protocol previously reported by Becker et al. 30 The entire macroscopic identifiable tumour or the area of the stomach with scarring indicating the site of the previous tumour (the tumour bed) was cross-sectioned serially at 0.5 cm intervals. These tissue sections were stained with haematoxylin and eosin, Verhoeff-Van Gieson staining for elastic fibres and periodic acid-Schiff (PAS) stain. The Van Gieson stain was used to distinguish between tumour desmosplasia and scarring as a result of chemotherapy and the PAS stain was used to help distinguish signet ring cells from histiocytes. Immunohistochemistry for cytokeratins was used in cases in which epithelial cells were not identifiable. Two pathologists (B.W., X.Z.) blinded to miR-21 expression data graded the slides. A three-point grading system, based on an estimation of the percentage of residual tumour tissue in relation to the macroscopically identifiable tumour bed, was used to evaluate pathological tumour response, as reported previously. 30 Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic accuracy of miR-21 expression for differentiating pathological responders from non-responders. The area under the ROC curve was calculated and the optimal cut-off value was defined as the point on the ROC curve with a maximum Youden index (sensitivity + specificity − 1). A value of P < 0.05 was considered to be statistically significant.
STATISTICAL ANALYSES
Results
A total of 42 patients with locally advanced CRC were included in the study, with a median age at diagnosis of 56 years (range 41 -68 years); 16 patients were classified as stage II and 26 patients as stage III (AJCC tumour, node, metastasis staging). Good/moderate differentiation was seen in 23 patients and poor differentiation in 19 patients. Quantitative real-time RT-PCR showed that miR-21 levels were significantly higher in 88.1% (37/42) of CRC tumour tissue compared with the paired NAT; the mean cycle threshold (CT) of miR-21 in CRC tumour tissue was significantly higher than in NAT (P < 0.001, Table 1 ).
The relationship between miR-21 and the various clinicopathological characteristics are summarized in Table 2 . High levels of miR-21 were significantly associated with advanced clinical stage (P < 0.001) and poor cell differentiation (P = 0.014). No correlation was observed between miR-21 level and age, gender, tumour size or tumour location.
A total of six patients had a grade 1 response to treatment, 19 patients were assessed as grade 2 and 17 patients as grade 3. In total, 25 patients were pathological responders and 17 were non-responders. The mean ± SD cycle threshold (CT) of miR-21 in the pathological responder group was significantly lower than in the nonresponder group (P = 0.001; Table 2 ).
The area under the ROC curve was 0.849 (95% confidence interval 0.729, 0.970; Fig.  1 ). The maximum optimal cut-off cycle threshold (CT) was 10.32 (Youden index 0.682), with sensitivity of 80.0% and specificity of 88.2%. Patients with miR-21 expression ≤ 10.32 were predicted to respond 
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to the current chemotherapy regimen, whilst those with miR-21 expression > 10.32 were predicted to be non-responders.
Discussion
The present study found that miR-21 was significantly overexpressed in CRC tumour tissues and that upregulation of miR-21 was associated with advanced clinical stage and poor cell differentiation. These findings support those of previous studies. For example, a trend was shown towards advanced cancer stage, poor differentiation, increased distant recurrence rate and more common vascular endothelial growth factor expression in pancreatic cancer patients with high miR-21 expression. 31 In another study, miR-21 was aberrantly overexpressed in gastric cancer tissue samples, and the knockdown of miR-21 dramatically decreased cell invasion and migration in vitro by regulating reversioninducing cysteine-rich protein with Kazal motifs (RECK), which is a tumour suppressor gene involved in cancer progression and angiogenesis. 32 It was also reported that miR-21 could target programmed cell death 4 at the post-transcriptional level and regulate cell proliferation and invasion in oesophageal 33 Taken together, these studies may help to explain the role of miR-21, not only in tumour pathogenesis but also in cancer progression and invasion in CRC patients.
One of the major challenges in oncology is the selection of appropriate patients who will benefit from neoadjuvant chemotherapy.
If chemotherapy is ineffective, the patient is needlessly exposed to its adverse effects and quality of life can be diminished. The molecular genetic basis of sensitivity and resistance to anticancer drugs is complex, involving multiple processes such as drug transport and metabolism, the mutation of drug targets, DNA repair and cell death pathways. Many studies have shown a correlation between miRNAs and carcinogenesis and cancer progression, 34 and a few have revealed a role for miRNAs in cancer chemoresistance. 35 Misexpression, mutation, or ectopic processing of miRNA genes disturbs the function of miRNAs, causing ectopic expression of target proteins that are involved in cancer drug responses and resulting in changes of chemosensitivity. In several studies miR-21 has been implicated in changes in chemosensitivity. For example, the growth inhibitory properties of topotecan (a clinical camptothecin analogue) on MCF7 (breast cancer) cells was increased by about 40% when they were transfected with anti-miR-21, partly due to the downregulation of Bcl-2, an antiapoptotic protein. 36 Expression of miR-21 was correlated with gemcitabine- induced apoptosis in cholangiocarcinoma and hepatocellular carcinoma, and the phosphatase and tensin homologue was found to be targeted by miR-21 and involved in chemosensitivity. 23, 27 Repressing miR-21 expression was also found to sensitize glioblastoma cells to VM-26 treatment via leucine-rich repeat flightless-interacting protein 1-mediated inhibition of nuclear factor κB signalling, a principal mechanism of tumour chemoresistance. 37 The results of the present study support these findings, showing a relationship between miR-21 level and pathological tumour regression in patients with advanced CRC, there being lower miR-21 expression in responders. An optimal cut-off cycle threshold (CT) of miR-21 was determined to be 10.32 for identifying pathological responders, and this achieved sensitivity of 80.0% and specificity of 88.2%, indicating that miR-21 may be a potential tissue marker of pathological tumour response in CRC patients.
In conclusion, miR-21 was significantly overexpressed in CRC tissues compared with normal tissues and upregulation of miR-21 was associated with advanced clinical stage and poor cell differentiation. Although the precise molecular mechanism of cancer chemoresistance requires further clarification, these data indicate that miR-21 may be a potential candidate biomarker for predicting of pathological tumour response to chemotherapy.
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